Arthur F Ryan sold $71k of REGN
director at REGENERON PHARMACEUTICALS, INC.. 100 shares at an average of $705.24, traded May 1, 2026, filed May 4, 2026.
Score components
- +15RoleDirector
- +8Trade size$71k at market
- 0Share of holdings soldSold 0.6% of holdings
- 0ClusterNo other insider selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001187443-26-000008, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 1, 2026 | SOpen-market sale Common Stock10b5-1 | -5 | $701.76 | $3,509 | 17,598 | May 4, 2026 |
| May 1, 2026 | SOpen-market sale Common Stock10b5-1 | -15 | $702.46 | $11k | 17,583 | May 4, 2026 |
| May 1, 2026 | SOpen-market sale Common Stock10b5-1 | -24 | $703.46 | $17k | 17,559 | May 4, 2026 |
| May 1, 2026 | SOpen-market sale Common Stock10b5-1 | -15 | $704.28 | $11k | 17,544 | May 4, 2026 |
| May 1, 2026 | SOpen-market sale Common Stock10b5-1 | -14 | $705.56 | $9,878 | 17,530 | May 4, 2026 |
| May 1, 2026 | SOpen-market sale Common Stock10b5-1 | -7 | $706.74 | $4,947 | 17,523 | May 4, 2026 |
| May 1, 2026 | SOpen-market sale Common Stock10b5-1 | -4 | $707.40 | $2,830 | 17,519 | May 4, 2026 |
| May 1, 2026 | SOpen-market sale Common Stock10b5-1 | -6 | $709.45 | $4,257 | 17,513 | May 4, 2026 |
| May 1, 2026 | SOpen-market sale Common Stock10b5-1 | -2 | $710.87 | $1,422 | 17,511 | May 4, 2026 |
| May 1, 2026 | SOpen-market sale Common Stock10b5-1 | -5 | $711.49 | $3,557 | 17,506 | May 4, 2026 |
| May 1, 2026 | SOpen-market sale Common Stock10b5-1 | -1 | $712.09 | $712 | 17,505 | May 4, 2026 |
| May 1, 2026 | SOpen-market sale Common Stock10b5-1 | -2 | $714.13 | $1,428 | 17,503 | May 4, 2026 |
Related signals
Other insiders at REGENERON PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 13Weak | REGENERON PHARMACEUTICALS, INC. | Kathryn Guarini director | $340k 400 shares | -40% | |
| 33Weak | REGENERON PHARMACEUTICALS, INC. | Marion McCourt EVP Commercial | $2.0M 2,346 shares | -16% | |
| 12Weak | REGENERON PHARMACEUTICALS, INC. | Kathryn Guarini director | $320k 400 shares | -40% | |
| 18Weak | REGENERON PHARMACEUTICALS, INC. | Huda Y Zoghbi director | $640k 800 shares | -32% | |
| 6Weak | REGENERON PHARMACEUTICALS, INC. | Arthur F Ryan director | $130k 200 shares | -1% | |
| 4Weak | REGENERON PHARMACEUTICALS, INC. | Arthur F Ryan director | $78k 100 shares | -1% | |
| 12Weak | REGENERON PHARMACEUTICALS, INC. | Arthur F Ryan director | $79k 100 shares | -1% | |
| 30Weak | REGENERON PHARMACEUTICALS, INC. | Huda Y Zoghbi director | $1.3M 1,638 shares | -49% | |
| 30Weak | REGENERON PHARMACEUTICALS, INC. | Jason Pitofsky SVP Controller | $1.6M 2,036 shares | -32% | |
| 19Weak | REGENERON PHARMACEUTICALS, INC. | Arthur F Ryan director | $78k 100 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.